Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA, Ansari SA, Alqahtani MH, Shay JW. · 2016
Read Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. by Jafri MA, Ansari SA, Alqahtani MH, Shay JW. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4915101.txt.
Introduction
Mohammad A. Jafri and co-authors reviewed telomeres and telomerase in cancer in 2016, plus therapies that target them. Telomeres cap chromosome ends and guard genome stability, but they shorten with each division until cells stall. Most cancers restart telomerase, the enzyme that rebuilds caps, and so survive endlessly.
Genome scans have mapped genes that set cap length and found hot-spot mutations in the telomerase gene's switch that switch it on. A backup lengthening path, tied to ATRX and DAXX faults, serves other tumors. Tests and drugs based on cap length and enzyme activity are in active build. The review weighs which tumors each approach fits, a guide for a target shared by most cancers.
Catalog record
| CREATOR | Jafri MA, Ansari SA, Alqahtani MH, Shay JW. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 83 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies By Mohammad A. Jafri, Shakeel A. Ansari, Mohammed H. Alqahtani, Jerry W. Shay Published in: Genome Medicine DOI: 10.1186/s13073-016-0324-x ABSTRACT Telomeres maintain genomic integrity in normal cells, and their progressive shortening during successive cell divisions induces chromosomal instability. In the large majority of cancer cells, telomere length is maintained by telomerase. Thus, telomere length and telomerase activity are crucial for cancer initiation and the survival of tumors. Several pathways that regulate telomere length have been identified, and genome-scale studies have helped in mapping genes that are involved in telomere length control. Additionally, genomic screening for recurrent human telomerase gene hTERT promoter mutations and mutations in genes involved in the alternative lengthening of telomeres pathway, such as ATRX and DAXX, has elucidated how these genomic changes contribute to the activation of telomere maintenance mechanisms in cancer cells. Attempts have also been made to develop telomere length- and telomerase-based diagnostic tools and anticancer therapeutics. Recent efforts have revealed key aspects of telomerase assembly, intracellular trafficking and recruitment to telomeres for completing DNA synthesis, which may provide novel targets for the development of anticancer agents. Here, we summarize telomere organization and function and its role in oncogenesis. We also highlight genomic mutations that lead to reactivation of telomerase, and mechanisms of telomerase reconstitution and trafficking that shed light on its function in cancer initiation and tumor development. Additionally, recent advances in the clinical development of telomerase inhibitors, as well as potential novel targets, will be summarized. BACKGROUND Cancer is generally an age-related genetic disease, manifesting only when normal cells accumulate genomic instability over a period of time and acquire the capability of replicative immortality. Telomere attrition during successive cell divisions induces chromosomal instability and contributes significantly to genomic rearrangements that can result in tumorigenesis. Telomeres, repetitive (TTAGGG) DNA–protein complexes at the ends of chromosomes, are crucial for the survival of cancer cells. They are maintained by an enzyme called telomerase in the vast majority of tumors. The mechanisms underlying telomere length (TL) maintenance and telomerase expression involve transcriptional, post-transcriptional and epigenetic regulation, and in-depth understanding of these mechanisms may provide novel biomarkers and targets for early detection of disease, determination of disease prognosis, and the development of therapeutics [1]. Telomeres protect chromosome ends from fusion and from being recognized as sites of DNA damage (Box 1). Dysfunctional telomeres, arising by critical shortening of telomeres in normal somatic cells during progressive cell divisions, elicit DNA damage responses (DDRs) that trigger cellular senescence. Cells that gain oncogenic changes bypass senescence and continue to divide (extended lifespan period) until multiple critically shortened telomeres initiate crisis (a period of complete replicative senescence, chromosome end-to-end fusions, and extensive apoptosis). This leads to breakage–fusion–bridge cycles in which two sister chromatids lacking telomeres fuse together, forming a bridge with a chromatin connection. During anaphase, the sister chromatids are drawn apart owing to movement towards opposite poles, resulting in the formation of uneven derivative chromosomes, leading to genomic instability. The period of crisis results in extensive cell death. However, certain rare cells escape crisis and maintain stable but usually shortened telomere lengths for continued cell growth, eventually progressing to a malignant phenotype. Cancer cells achieve proliferative immortality by activating or upregulating the normally silent human TERT gene (hTERT) that encodes telomerase, a protein with reverse transcriptase activity that complexes with other proteins and a functional RNA (encoded by hTR, also called hTERC) to make a ribonucleoprotein enzyme complex. Rarely, another DNA recombination mechanism termed alternative lengthening of telomeres (ALT) reverses telomere attrition in order to bypass senescence. Although hTERT is usually silenced in almost all somatic cells, it is significantly expressed in ~90 % of human cancers. The details of the underlying mechanisms of hTERT activation are still being elucidated, but they mainly include mutations in the hTERT promoter, alterations in alternative splicing of hTERT pre-mRNA, hTERT amplification, epigenetic changes, and/or disruption of telomere position effect (TPE) machinery [2]. Recent reports have implicated two cancer-specific hTERT promoter mutations (mainly C˃T transitions) in the activation of telomerase in cancer cells [3, 4]. These mutations, which are located either −124 base pairs (bp) or −146 bp upstream from the TERT translation start site [5, 6], have been found to be associated with increased telomerase activity [7]. Therefore, molecular mechanisms that regulate hTERT expression and telomerase assembly have been subjected to intense investigation. Studies using telomerase inhibition strategies have established that robust hTERT inhibition can lead to progressive telomere shortening and eventually cancer cell death. Several approaches, including use of small-molecule inhibitors, antisense oligonucleotides, immunotherapy, and G-quadruplex stabilizers have been employed to inhibit telomerase function [8]. Currently, many anti-telomerase therapeutics are being evaluated in clinical trials against a variety of cancer types. The following sections will cover recent developments in the area of telomere and telomerase biology, their implications for understanding mechanisms underlying cancer and for the development of cancer therapies, as well as outstanding questions for the field. TELOMERES: ORGANIZATION, FUNCTION AND ASSOCIATION WITH CANCER Recent studies have significantly contributed to our understanding of telomere organization in the nucleus, telomere profiling for risk stratification, and the signaling pathways that mediate modulation of telomere structural component proteins or factors to regulate gene transcription [9]. Telomeres consist of a capping structure, which is a specialized nucleoprotein structure consisting of DNA and shelterin protein complexes. Telomeric DNA contains a variable number of G-rich, non-coding, tandem repeats (10–15 kilobases (kb) long in humans at birth) of double-stranded DNA sequence, 5′-(TTAGGG)n-3′, followed by a terminal 3′ G-rich single-stranded overhang (150–200 nucleotide long). The 3′ G-rich overhang facilitates telomeric DNA in forming a higher-order structure in which the 3′ single-stranded overhang folds back and invades the homologous double-stranded TTAGGG region, forming a telomeric loop (T-loop) that provides 3′-end protection by sequestering it from recognition by the DDR machinery [10]. The proteins associated with telomeres are called the shelterin complex, which consists of three core shelterin subunits, TRF1 and TRF2, which directly recognize and bind duplex TTAGGG repeats, and POT1, which recognizes and binds single-stranded TTAGGG overhangs. These three proteins are interconnected by three additional shelterin proteins, TIN2, TPP1 and RAP1, forming a complex that enables DDR surveillance machinery to distinguish telomere DNA from sites of genomic DNA damage (Fig. 1). The shelterin complex performs critical and distinct functions that ensure telomere stability. For example, TRF2 is required for T-loop formation and maintenance of ATM-mediated DDR suppression and repression from non-homologous end joining [11]. TRF1 has a central role in controlling replication of telomeric DNA [12] while POT1 associates with TPP1 to bind the single-stranded 3′ overhang and repress ATR-mediated DDR by preventing the recruitment of replication protein A (RPA) [13]. TIN2 is essential to the overall integrity of the shelterin complex as it links the TPP1/POT1 heterodimer to TRF1 and TRF2, and stabilizes TRF1 and TRF2 associations with telomeric DNA [14, 15]. RAP1 interacts with TRF2 and improves its selective binding to telomeric DNA [16].Fig. 1Schematic representation of telomeric DNA and components of the shelterin complex. Telomeres comprise a specialized nucleoprotein-capping structure consisting of DNA and shelterin protein complexes. Telomeric DNA contains a variable number of G-rich, non-coding, tandem repeats of the double-stranded DNA sequence 5′-(TTAGGG)n-3′, followed